Press release
Progressive Multifocal Leukoencephalopathy Market Expected to rise, 2034 | 34NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, expected to drive market
Progressive Multifocal Leukoencephalopathy market growth
The Progressive Multifocal Leukoencephalopathy market report [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Progressive Multifocal Leukoencephalopathy market size, share, Progressive Multifocal Leukoencephalopathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Progressive Multifocal Leukoencephalopathy market size growth forward.
Some of the key highlights from the Progressive Multifocal Leukoencephalopathy Market Insights Report:
*
Several key pharmaceutical companies, including NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, and others, are developing novel products to improve the Progressive Multifocal Leukoencephalopathy treatment outlook.
*
The Progressive Multifocal Leukoencephalopathy (PML) market is expected to grow steadily, with a projected compound annual growth rate (CAGR) of about 3% from 2024 to 2034. This growth in the 7MM is driven by the emergence of innovative treatments like NT-I7 Monotherapy, increased use of immunosuppressive therapies, and rising awareness of PML.
*
In 2023, DelveInsight estimated approximately 3,947 new PML cases in the 7MM, with the U.S. accounting for 43%, EU4 and the UK contributing 42%, and Japan representing 16%.
*
The absence of FDA-approved therapies highlights a significant unmet need for effective treatments, as current options focus only on immune restoration with limited success. Developing therapies for PML is particularly challenging due to the disease's complex pathophysiology and the virus's resistance to antivirals. Additionally, the small patient population and high mortality rates hinder investment in drug development, making commercial viability difficult for pharmaceutical companies.
*
As per DelveInsight analysis, the Progressive Multifocal Leukoencephalopathy market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Progressive Multifocal Leukoencephalopathy Market Landscape [https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Overview
Progressive Multifocal Leukoencephalopathy (PML) is a severe neurological condition caused by the activation of the John Cunningham virus (JCV), leading to the demyelination of central nervous system (CNS) white matter. It primarily affects individuals with weakened immune systems, such as those with HIV/AIDS, hematological malignancies, or those on immunosuppressive therapies. PML can also occur in patients undergoing organ transplants or with autoimmune disorders, though these cases account for less than 10%.
Symptoms vary depending on the location of CNS lesions and may include cognitive decline, vision loss, speech difficulties, weakness, coordination issues, sensory loss, and seizures in about one-third of cases. Diagnosis involves clinical evaluation, MRI to detect characteristic white matter lesions, and confirmation through JCV DNA detection in cerebrospinal fluid (CSF) via PCR or brain biopsy.
PML has a poor prognosis, with untreated patients often dying within 2-6 months and rarely surviving beyond a year. Early and accurate diagnosis is crucial for management.
Do you know the treatment paradigms for different countries? Download our Progressive Multifocal Leukoencephalopathy Market Sample Report [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Epidemiology Insights
*
DelveInsight's epidemiology model estimates that the United States recorded approximately 1,687 incident cases of Progressive Multifocal Leukoencephalopathy (PML) in 2023. This figure is expected to increase over the forecast period (2024-2034) due to advancements in diagnostic methods and an aging population.
*
In the EU4 and the UK, Germany reported the highest number of PML cases in 2023, with around 420 incidents, followed by France with approximately 342 cases, and the UK with nearly 339 cases.
Progressive Multifocal Leukoencephalopathy Epidemiology Segmentation
DelveInsight's Progressive Multifocal Leukoencephalopathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Progressive Multifocal Leukoencephalopathy historical patient pools and forecasted Progressive Multifocal Leukoencephalopathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Progressive Multifocal Leukoencephalopathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
*
Progressive Multifocal Leukoencephalopathy Prevalence
*
Age-Specific Progressive Multifocal Leukoencephalopathy Prevalence
*
Gender-Specific Progressive Multifocal Leukoencephalopathy Prevalence
*
Diagnosed and Treatable Cases of Progressive Multifocal Leukoencephalopathy
Visit for more @ Progressive Multifocal Leukoencephalopathy Epidemiological Insights [https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Market Outlook
The current management of Progressive Multifocal Leukoencephalopathy (PML) focuses on immune restoration to improve survival, with antiretroviral therapy and addressing immunosuppressive causes playing key roles. While various agents, including cytosine arabinoside, cidofovir, and mefloquine, have been used, their effectiveness has not been confirmed in rigorous clinical trials. Notably, cytarabine has shown no significant impact on disease progression in randomized studies, and cidofovir has yielded inconsistent results, with survival more closely tied to immune recovery than to specific treatments.
Emerging therapies like NeoImmuneTech's NT-I7 (efineptakin alfa) suggest a shift towards immune-enhancing strategies, but the treatment pipeline for PML remains underdeveloped, dominated by early-phase candidates. This highlights an urgent need for innovative therapies to improve outcomes. The prognosis for most PML patients remains poor, emphasizing the critical gap in effective treatment options.
Progressive Multifocal Leukoencephalopathy Emerging Drugs
*
NT-I7 Monotherapy (efineptakin alfa): NeoImmuneTech
Progressive Multifocal Leukoencephalopathy Key Companies
*
NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, and others
For more information, visit Progressive Multifocal Leukoencephalopathy Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Scope of the Progressive Multifocal Leukoencephalopathy Market Report:
*
11 Years Forecast
*
7MM Coverage
*
Descriptive overview of Progressive Multifocal Leukoencephalopathy, causes, signs and symptoms, diagnosis, treatment
*
Comprehensive insight into Progressive Multifocal Leukoencephalopathy epidemiology in the 7MM
*
Progressive Multifocal Leukoencephalopathy marketed and emerging therapies
*
Progressive Multifocal Leukoencephalopathy companies
*
Progressive Multifocal Leukoencephalopathy market drivers and barriers
Table of Contents:
1 Progressive Multifocal Leukoencephalopathy Market Key Comprehensive Insights
2 Progressive Multifocal Leukoencephalopathy Market Report Introduction
3 Competitive Intelligence Analysis for Progressive Multifocal Leukoencephalopathy
4 Progressive Multifocal Leukoencephalopathy Market Analysis Overview at a Glance
5 Executive Summary of Progressive Multifocal Leukoencephalopathy
6 Progressive Multifocal Leukoencephalopathy Epidemiology and Market Methodology
7 Progressive Multifocal Leukoencephalopathy Epidemiology and Patient Population
8 Progressive Multifocal Leukoencephalopathy Patient Journey
9 Progressive Multifocal Leukoencephalopathy Treatment Algorithm, Progressive Multifocal Leukoencephalopathy Current Treatment, and Medical Practices
10 Key Endpoints in Progressive Multifocal Leukoencephalopathy Clinical Trials
11 Progressive Multifocal Leukoencephalopathy Marketed Therapies
12 Progressive Multifocal Leukoencephalopathy Emerging Therapies
13 Progressive Multifocal Leukoencephalopathy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Progressive Multifocal Leukoencephalopathy
16 Progressive Multifocal Leukoencephalopathy Market Key Opinion Leaders Reviews
18 Progressive Multifocal Leukoencephalopathy Market Drivers
19 Progressive Multifocal Leukoencephalopathy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Progressive Multifocal Leukoencephalopathy Epidemiology 2034
DelveInsight's "Progressive Multifocal Leukoencephalopathy - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Progressive Multifocal Leukoencephalopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Progressive Multifocal Leukoencephalopathy Pipeline 2024
"Progressive Multifocal Leukoencephalopathy Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Progressive Multifocal Leukoencephalopathy market. A detailed picture of the Progressive Multifocal Leukoencephalopathy pipeline landscape is provided, which includes the disease overview and Progressive Multifocal Leukoencephalopathy treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=progressive-multifocal-leukoencephalopathy-market-expected-to-rise-2034-34neoimmunetech-inhibikase-therapeutics-neurimmune-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer:Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Multifocal Leukoencephalopathy Market Expected to rise, 2034 | 34NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, expected to drive market here
News-ID: 3860354 • Views: …
More Releases from ABNewswire
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Progressive
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 - …
"The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.
The progressive multifocal leukoencephalopathy treatment market size is…
Progressive Multifocal Leukoencephalopathy Treatment Market Size 2034
DelveInsight's 'Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast - 2034' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Progressive Multifocal Leukoencephalopathy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report
• According to DelveInsight's analysis, the incident cases of PML in the 7MM were approximately 4…
Benefits of Progressive Web App for A Business
Progressive Web Apps (PWAs) offer numerous benefits for businesses seeking to enhance their online presence and improve user experiences. Firstly, PWAs are designed to work seamlessly across various devices and platforms, including desktops, smartphones, and tablets. This cross-platform compatibility ensures that businesses can reach a wider audience without the need for separate native apps for each operating system, thereby reducing development costs and maintenance efforts.
If you are planning to grow…
Seminar on Progressive Farming
Shri Venkateshwara University/VGI Meerut in collaboration with Bhartiya Kisan Union (Meerut Division) is organizing a 1 day seminar on Progressive farming & farmer the foundation of development on Nov 3rd.In this seminar, the National Organization Minister of All India Farmer's Organization Mr Dinesh Kulkarni, Padamshree Mr Bharat Bhushan Tyagi, & the State Agriculture Minister Mr Baldev Singh Aulakh will take part.Apart from these renowned agriculture scientists, environmentalists, bureaucrats & 400…
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is…
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability.
Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and…
